HLA DR Genome Editing with TALENs in Human iPSCs Produced Immune-Tolerant Dendritic Cells.

Stem Cells International
Yoo-Wook KwonHyo-Soo Kim

Abstract

Although human induced pluripotent stem cells (iPSCs) can serve as a universal cell source for regenerative medicine, the use of iPSCs in clinical applications is limited by prohibitive costs and prolonged generation time. Moreover, allogeneic iPSC transplantation requires preclusion of mismatches between the donor and recipient human leukocyte antigen (HLA). We, therefore, generated universally compatible immune nonresponsive human iPSCs by gene editing. Transcription activator-like effector nucleases (TALENs) were designed for selective elimination of HLA DR expression. The engineered nucleases completely disrupted the expression of HLA DR on human dermal fibroblast cells (HDF) that did not express HLA DR even after stimulation with IFN-γ. Teratomas formed by HLA DR knockout iPSCs did not express HLA DR, and dendritic cells differentiated from HLA DR knockout iPSCs reduced CD4+ T cell activation. These engineered iPSCs might provide a novel translational approach to treat multiple recipients from a limited number of cell donors.

References

Sep 1, 1996·The Journal of Clinical Investigation·Z LiuN Suciu-Foca
Mar 27, 2001·Transplantation Proceedings·G CiancioJ Miller
Jul 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Micha DrukkerNissim Benvenisty
Feb 9, 2005·The Journal of Experimental Medicine·Isabelle J Fugier-VivierSuzanne T Ildstad
Sep 12, 2006·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Ingo KaczmarekBruno Reichart
Dec 13, 2006·Experimental Hematology·Michael TillsonClinton D Lothrop
Jan 23, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Loredana FrascaClara Maria Ausiello
Jul 10, 2008·Nature Biotechnology·Norio NakatsujiKatsushi Tokunaga
May 7, 2009·Current Opinion in Organ Transplantation·Kathryn M Silk, Paul J Fairchild
Dec 29, 2009·Cell Stem Cell·Miguel Angel EstebanDuanqing Pei
Aug 9, 2011·Methods in Molecular Biology·Kathryn M SilkPaul J Fairchild
Oct 11, 2011·Nature Methods·Hyojin KimJin-Soo Kim
Apr 28, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jutta Horejs-HoeckAlbert Duschl
Jul 14, 2012·Human Immunology·Dominique CharronReem Al-Daccak
Dec 18, 2012·Circulation Research·Laura LaudenReem Al-Daccak
Feb 2, 2013·Circulation Research·Patricia E de AlmeidaJoseph C Wu
Feb 19, 2013·Nature Biotechnology·Yongsub KimJin-Soo Kim
May 1, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Laura RiolobosDavid W Russell
May 15, 2013·Trends in Biotechnology·Thomas GajCarlos F Barbas
Apr 23, 2014·Nature Biotechnology·Xuebing WuPhillip A Sharp
Sep 1, 2017·Nature Communications·Asuka MorizaneJun Takahashi
Dec 17, 2017·Molecular Therapy. Nucleic Acids·Zhao ZhangQizhou Lian

❮ Previous
Next ❯

Software Mentioned

GraphPad Prism
TALEN
GraphPad

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.